Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Italian biopharmaceutical firm Dompe farmaceutici has sold rights for iodine-131-labelled humanized monoclonal antibody fragment FabOvar to Advanced Accelerator Applications (AAA).
Subscribe to our email newsletter
Currently under preclinical development, FabOvar is intended as an treatment for ovarian carcinoma.
AAA CEO Stefano Buono said in previous studies FabOvar is an evolution of a previous murine monoclonal antibody fragment which was shown to be well tolerated and induced a positive response when administered as a single administration in patients but which was seen to induce inadequate immunological response.
Dompe CEO Eugenio Aringhieri said they believe that the targeted and personalized research programs of AAA will offer significant treatment advantages compared to currently available products.
Further terms of the agreement were not been disclosed.